RedHill Biopharma Ltd. (2RH0.F)
| Previous close | 0.3520 |
| Open | 0.3775 |
| Bid | 0.4070 x N/A |
| Ask | 0.4585 x N/A |
| Day's range | 0.3775 - 0.3775 |
| 52-week range | 0.2440 - 3.5800 |
| Volume | |
| Avg. volume | 677 |
| Market cap | 14.327M |
| Beta (5Y monthly) | 3.46 |
| PE ratio (TTM) | 0.11 |
| EPS (TTM) | 3.4500 |
| Earnings date | 10 June 2024 - 14 June 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireRedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent Notice of Allowance covering opaganib[1] as a therapyg for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus) from the Chinese National Intellectual Property Administration (CNIPA), valid through 2035 (Chinese Patent Application No.: 202110229970.9 issued April 29, 2024).
- PR Newswire
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes' (ACESO) U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment. RHB-107 (upamostat) is the first drug being tested in this platform study. Funded through non-dilutive external sources, including the U.S. Department of D
Simply Wall St.RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)
RedHill Biopharma ( NASDAQ:RDHL ) Full Year 2023 Results Key Financial Results Net income: US$23.9m (up from US$71.7m...
